Fort Bliss

Researchers are evaluating the effectiveness of adding LY3537982 (olomorasib) to standard anti-cancer drugs compared to standard treatment alone in participants with untreated advanced non-small cell lung cancer (NSCLC) that has a specific KRAS G12C gene mutation. This pivotal Phase 3 trial includes participants with locally advanced or metastatic NSCLC and considers their programmed death-ligand 1 (PD-L1) expression levels. The study includes multiple parts: Dose Optimization, Part A, and Part B are randomized, while Safety Lead-In for Part B and Part C are non-randomized. Treatments being assessed include LY3537982 taken orally, pembrolizumab administered intravenously, and standard chemotherapy drugs such as cisplatin, carboplatin, and pemetrexed given intravenously. Participants receive these treatments according to their assigned groups based on their PD-L1 expression and tumor histology. Participants will be monitored with regular assessments including measuring disease progression, safety evaluations, and treatment emergent adverse events for up to approximately one year, with overall study participation potentially lasting up to three years depending on individual response and health status. Outcome measures focus on progression-free survival and safety, capturing any adverse events from the start of treatment until disease progression or death.

Researchers are evaluating the safety, effectiveness, and tolerability of two repetitive transcranial magnetic stimulation (rTMS) treatments targeting the dorsolateral prefrontal cortex to reduce depression symptoms in U.S. military service members and veterans with a history of concussion or mild traumatic brain injury (TBI). This randomized, double-blind, Bayesian adaptive trial focuses on current and former service members who experience depressive symptoms following concussion, a condition common in this population. Participants will receive either individualized connectome targeted accelerated intermittent Theta Burst Stimulation (aiTBS) or scalp-targeted aiTBS using active rTMS devices, with a sham rTMS group for comparison. The study involves multiple sessions where these treatments are applied to assess their therapeutic potential for depression related to concussion. During the study, participants will be monitored through clinical assessments including the Montgomery-Asberg Depression Rating Scale (MADRS) to measure changes in depression severity from baseline to post-intervention and up to six months follow-up. Researchers will track treatment response, remission duration, and adverse events. The total time commitment includes baseline screening, treatment sessions, and follow-up visits to evaluate long-term outcomes and safety.

Researchers are investigating the feasibility of providing early access to mental healthcare during treatment for musculoskeletal sarcoma, including bone and soft tissue sarcomas. This study aims to explore how early psychiatric care referrals might affect depression, anxiety, surgical outcomes, and patient satisfaction in individuals undergoing surgery for sarcoma. The study is a randomized pilot trial conducted to assess these associations and improve quality of life during sarcoma treatment. Participants in this study are referred to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences as the main intervention. The study does not prescribe specific psychiatric treatments beyond this referral. The focus is on assessing the impact of early behavioral healthcare alongside surgical treatment for the primary sarcoma at MSK. During the study, participants will attend scheduled visits over a two-year period, allowing researchers to monitor their mental health and surgical outcomes. The main measure is the number of participants who complete these visits. Assessments include self-reported depression and anxiety, health-related quality of life, and patient satisfaction. The study tracks the effects of early psychiatric referral on these outcomes to understand its potential benefits throughout the treatment process.